Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection
A Randomized Double Blind Controlled Proof of Concept Study of the Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma With Successful Surgical Resection of at Least 90 % of the Initial Tumor and CMV Infection Demonstrated Histologically and Immunohistochemically.
Sponsor: Karolinska Institutet
Listed as NCT00400322, this NA trial focuses on Cytomegalovirus Infection and Glioblastoma Multiforme and remains completed. Sponsored by Karolinska Institutet, it has been updated 7 times since 2006, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Mar 2021 — Jul 2024 [monthly]
Completed NA
Status: Unknown Status → Completed
-
Jan 2021 — Mar 2021 [monthly]
Unknown Status NA
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status NA
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status NA
First recorded
Aug 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Karolinska Institutet
- Karolinska University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .